Bio-Rad Q3 2026 earnings: revenue returned to currency-neutral growth, ddPCR stayed strong, and 2027 risks remain. Earnings Call Insights: Bio-Rad Laboratories (BIO) Q3 2026 “The third quarter represented another step forward in our efforts to improve Bio-Rad's operating and financial performance.” (President & COO Jonathan DiVincenzo)…
In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Crispr Therapeutics AG, with a price target of $50.00. According to TipRanks, Issi is an analyst with an average return of -5.6% and a 36.64% success rate. Issi…
Under the proposed terms, the SPAC would acquire 100% of SkinJec in exchange for newly issued common stock of the combined company. Medicus said it seeks to retain majority economic and voting ownership of the separately listed entity, preserving shareholder participation…
Q-CTRL builds educational and developer tools that help biopharmaceutical experts take advantage of quantum computing technology to solve chemical problems and improve chemical accuracy. Today’s chemical problems experience bottlenecks arising from the translation of a quantum physical problem into a…
Pakka Limited (Pakka) reduced planned preferential-issue proceeds to Rs 114.62 crore from Rs 129.91 crore after convertible warrants were undersubscribed. By September 30, 2026, Pakka had received Rs 51.09 crore, comprising fully subscribed equity shares and the 25% upfront payment on subscribed warrants, with the amount…
Maravai Lifesciences unit TriLink said Tuesday it has opened its Good Manufacturing Practice enzyme manufacturing facility in Jupiter, Florida. The facility supports a coordinated supply of key... Maravai LifeSciences Holdings, Inc. Biotechnology & Medical Research Maravai Lifesciences Unit TriLink Opens Enzyme…
Maravai LifeSciences Holdings, Inc. reiterated earnings guidance for the year 2026. For the year, the company is reiterating 2026 revenue guidance range of $205 million to $215 million.... Published on 08/06/2026 at 04:01 pm EDT Maravai LifeSciences Holdings, Inc. reiterated earnings guidance for the year 2026. For…
Release Date: November 04, 2026 All three late-stage modifier gene therapy programs (OCU400, OCU410-ST, OCU410-GA) are now in Phase 3, with top-line data expected for OCU400 in Q1 2027 and OCU410-ST in Q2 2027. Ocugen Inc (NASDAQ:OCGN) completed enrollment in the Phase 3 LIMELIGHT trial for OCU400 (140 patients) and process…
Ascentage Pharma (06855.HK) announced that four of its research programs have been selected for the 68th American Society of Hematology (ASH) Annual Meeting, covering olverembatinib, lisaftoclax, APG-5918 and APG-3288. Among them, the EED inhibitor APG-5918 has secured an oral presentation slot…
Smart Topics: Rama SmartSearch identifies popular industry keywords as "Smart Topics" and searches article titles for related industry keywords. You may simply combine keywords to narrow search results. Alternatively, you may use the "AND" operator to also combine keywords. You…
Biotechnology, gene editing, biopharma platforms, and clinical pipelines.
An article joins this feed when it matches these terms. Each one is also a search of its own.